Seaport begins phase 2a trial of GlyphAgo for generalized anxiety disorder with sleep disturbance, testing liver-sparing agomelatine dosing and tracking sleep, anxiety outcomes.
Advertisement
Advertisement
- ADHD
- Addiction & Substance Use
- Alzheimer Disease & Dementia
- Anxiety Disorders
- Cannabis
- Case Discussions
- Comorbidity
- Consultation-Liaison Psychiatry
- Cultural Psychiatry
- Drug Watch
- Eating Disorders
- Emergency Psychiatry
- Ethics
- Forensic Psychiatry
- Integrative Psychiatry
- Life Cycle Psychiatry
- Mental Health Awareness Month
- Mood Disorders
- Neuromodulation
- Neuropsychiatry
- Obsessive-Compulsive Disorders
- PTSD, Trauma & Stress Disorders
- Personality Disorders
- Psychedelics & Cannabis
- Psychiatry & Society
- Psychopharmacology
- Psychosomatics
- Psychotherapy
- Schizophrenia/Psychosis
- Sleep-Wake Disorders
- Special Populations
- Suicide
- Tardive Dyskinesia
- Technology & Psychiatry